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1. Introduction
  Actin has been deeply studied and concluded as an 
evolutionary conserved molecule and one of the major 
cytoskeletal components in eukaryotic cells including 
tumor cells[1, 2]. Actin exists in two forms, the monomeric 
actin and microfilament that is a polymerized form of 
monomeric actin. Each microfilament has two different 
specific ends, at which polymerization happens at different 
rates, a fast growing or ‘barbed’ end and a slow-growing or 
‘pointed’ end, which keep in a dynamic balance between 
monomeric and polymerized actins[2-4]. The polymerization, 
depolymerization and redistribution of actin microfilaments 
are delicately regulated by a variety of extracellular and 
intracellular factors[1, 5, 6]. At present, more and more study 
results have indicated that microfilaments are involved 
in various cellular functions including cell morphology, 
migration, ion channels activity, secretion, apoptosis and 
cell survival. Therefore, disruption of microfilaments by 
chemical agents, such as cytochalasins, can cause severe 
damages in cell function, even culminating in cell death or 
apoptosis[7-10].
  Cytochalasins are a group of chemical agents, which are 
mainly isolated from symbiotic fungi in tropical countries 
and areas. Cytochalasins are capable of permeating cell 
membranes, binding to actin and altering its polymerization. 
At present, several lines of evidence have indicated 
that cytochalasin B and E possess somewhat anticancer 
activities[11, 12]. However, cytochalasin D (Cyt D) is thought 
to be the most specific for the actin microfilaments among 
various cytochalasins at present[13]. Functionally, Cyt D 
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can specifically binds to the barbed end of growing actin 
microfilaments and at last causes inhibition or disruption 
of actin microfilaments by altering actin polymerization[2]. 
Therefore, it is reasonable to consider that Cyt D may 
be a candidate cytotoxic agent for tumor therapy. In this 
study, we used murine colorectal tumor cell line CT26 to 
investigate the possible Cyt D’s anticancer activities. Our 
results showed that Cyt D can induce CT26 cell apoptosis 
and proliferation in vitro and suppressed tumor growth and 
angiogenesis in vivo, suggesting its therapeutic values in 
cancer treatment.
2. Materials and methods
2.1. Cell culture
  Murine colorectal carcinoma cell line CT26 (CT26) was 
purchased from the American Type Culture Collection 
(ATCC, Manassas, VA). CT26 cells were cultured in RPMI1640 
(Gibical) supplemented with 10% fetal bovine serum, 100 IU/mL
penicillin and 100 mg/mL streptomycin at 37 曟 in a 
humidified atmosphere with 5% CO2. The logarithmic phase 
cells were used for subsequent experiments.
2.2. MTT assay
  For MTT assay, CT26 cells in logarithmic growth were 
trypsinized and harvested, and then the cells were seeded 
onto a 96-well plate. After 24 h, fresh RPMI 1640 medium 
containing different concentrations of Cyt D (0.75, 1.25, 2.5, 
5.0, 7.5, 10 and 15 毺g/mL) was added at 100 毺L per well 
respectively and each concentration has 6 replicate wells. 
After incubation for different time intervals, 10 毺L of MTT 
(5 mg/mL) was added to each well and the cells were further 
incubated at 37 曟 for 4 hours. Then the supernatant was 
removed and 100 毺L DMSO was added into each well. In 
the end, the absorbance (A value) at wavelength of 490 nm 
was measured with a microplate reader (Bio-Tek EXL808).
2.3. Detection of cell apoptosis in vitro
    A TUNEL-based apoptosis detection was performed using 
TiterTACS In Situ Detection Kit (Trevigen) as described 
in previous study[14]. In brief, CT26 cells were seeded in 
96-well plates and incubated for 16 h in the presence or 
absence of tested drugs at a concentration of the optimum 
dose decided from the above MTT results. Thereafter, 
cells were fixed and nick-end labeled as recommended 
by the manufacturer’s protocol. The absorbance at 450 
nm (A450 nm), corresponding to the amount of nick-
ends, was normalized to the amount of cells, as evaluated 
from crystal violet staining (A540 nm). For purpose of 
clearly representation, all A450 nm/A540 nm signals were 
normalized to the signal obtained from unlabeled sample 
(cells treated with DMSO and without nick-end labeling) as 
negative control. For positive control, the nuclease-treated 
cells were treated with TACS Nuclease after fixation, and 
then nick-end labeled. 
2.4. Establishment of tumor models
  Female BALB/c mice at 6 to 8 weeks of age were used for 
establishment of tumor models. To established tumor model, 
BALB/c mice were injected s.c. with 2伊106 corresponding 
tumor cells in the dorsal area. The animal protocols in this 
study were approved by the College’s Animal Care and Use 
Committee. 
2.5. Determination of optimum effective dose
  CT26-bearing BABL/c mice were randomly divided into 
six groups (n = 5 for each group). Treatment started when 
tumor volume was about 90 mm3. These mice were injected 
i.v. with various does of Cyt D (12.5, 25, 50 and 100 mg/kg in 
200 毺L DMSO) and DMSO (200 毺L), respectively. All these 
reagents were given every 3 days for 15 days. The mice were 
sacrificed on day 18, and tumor tissues were excised and 
weighed. The optimum effective dose of Cyt D for further 
experiments was decided according to the tumor weights.
2.6. In vivo observations of antitumor activities
  Tumor-bearing mice injected with CT26 cells were divided 
into two groups (n = 10 for each group) and i.v. injected 
with Cyt D (50 mg/kg in 100 DMSO) and DMSO (100 毺L, as 
negative control) very 3 days for 21 days, respectively. The 
tumor volumes and survival time were observed. Tumor 
volumes were calculated according to the formula: V = 0.52a 
伊 b2, where a is the largest superficial diameter and b is 
the smallest superficial diameter. The mice were sacrificed 
when they became moribund and the sacrificed date was 
then recorded to calculate the survival time. In addition, 
tumor tissues were also excised, fixed in 10% formalin and 
frozen in -80 for detections of microvessel density.
2.7. Detection of microvessel density in tumor tissues
  For microvessel density (MVD) analysis in tumor tissues, 
frozen sections were fixed in acetone, incubated, and stained 
with an antibody reactive to CD31 as we previously done[15]. 
The sections were then stained with labeled streptavidin 
biotin reagents (Dako LSAB kit, peroxidase; Dako). Vessel 
density was determined by counting the number of 
microvessels per high-power field (hpf) in the sections. 
2.8. Alginate encapsulation assay
  Alginate encapsulated tumor cell assays were performed 
as previously described[16]. Briefly, CT26 cells were 
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resuspended in a 1.5% solution of sodium alginate and 
added dropwise into a swirling 37 曟 solution of 250 mM 
calcium chloride. Alginate beads were formed containing 
approximately 1伊105 tumor cells per bead. Experiment mice 
were then anesthetized, and four beads were implanted 
subcutaneously into an incision made on the dorsal side. 
Incisions were closed with surgical clamps. After 14 days, 
mice were injected intravenously with 100 毺L of a 100 mg/kg
FITC-dextran solution (Sigma). Beads were surgically 
removed and FITC-dextran quantified against a standard 
curve of FITC-dextran. 
2.9. Statistical analysis
  An unpaired Student’s t-test was used to compare the 
statistical differences in the experimental values between 
two samples. Survival curves were constructed according 
to the Kaplan-Meier method and statistical significance 
was determined by the log-rank test. A P values < 0.05 was 
considered statistically significant. Error bars represent SEM 
unless otherwise indicated.
3. Results
3.1. Inhibition of cell proliferation by Cyt D 
  MTT assay was used to determine the cell proliferation. The 
results showed that Cyt D treatment caused significantly 
inhibition of cell proliferation in vitro. Compared with the 
CT26 cells treated with the control DMSO, the CT26 cells 
treated with Cyt D showed significant suppression of cell 
proliferation and the suppression was in a pattern of dose 
and time dependent manner (Figure 1). The percentage 
inhibition of CT26 cell proliferation by 0.75 and 10 毺g/mL 
Cyt D was (12.3 依 2.3) % and (73.9 依 7.1) %, respectively 
(Figure 1A). Moreover, when CT26 cells were treated by 
10 毺g/mL Cyt D, the percentage inhibition was (41.2 依 
4.2) % for 24 hours and (68.3 依 6.9) % for 96 hours (Figure 
1B). When compared with the DMSO-treated CT26 cells, 
the values from the Cyt D-treated CT26 cells in every dose 
(Figure 1A) and at every time point (Figure 1B) showed 
significant difference (P < 0.05 or less).
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Figure 1. Inhibition of cell proliferation by Cyt D.
CT26 cells were cultured in various dose of Cyt D (0.24~15 毺g/mL). 
Cell proliferation was detected by Proliferation ELISA kit. Data are 
expressed as means 依 SEM, *P < 0.01 or less, compared to the various 
dose or DMSO-treated CT26 cells.
3.2. Induction of cell apoptosis in vitro by Cyt D
  A TUNEL-based assay that detects the amount of nick-
ends generated as a result of DNA fragmentation during 
apoptosis was performed in a commercial Kit and the 
results were relatively compared to the negative control (as 
1) (Figure 2). The amount of nick-ends in the CT26 cells 
treated with DMSO was low (1.28 依 0.18), with a similar level 
as the unlabeled negative cells. In contrast, in CT26 cells 
treated with Cyt D the absorbance signals were significantly 
increased and almost reached the level in the nuclease-
treated positive cells (5.28 依 0.46 versus 5.91 依 0.63), 
suggesting Cyt D is a potential effective cytotoxic agent for 
cancer therapy.
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Figure 2. Induction of cell apoptosis in vitro by Cyt D. 
CT26 cells were treated for 16 h with Cyt D or DMSO. Thereafter, 
cells were fixed and nick-end labeled. The amount of nick-ends 
(A450 nm) was divided by the amount of cells as evaluated by crystal 
violet staining (A540 nm). Graph shows the results of a representative 
experiment run in triplicate and expressed as means 依 SEM, *P < 
0.001, # > 0.05.
3.3. The optimum effective dose of Cyt D
  In order to choose an optimum effective dose of Cyt D for 
use in the in vivo, CT26-bearing BABL/c mice were treated 
with Cyt D at different dose. Our results demonstrated 
that 12.5 to 100 mg/kg Cyt D showed in a pattern of dose-
dependent (Figure 3). The mice treated with 12.5 and 25 mg/kg
Cyt D showed somewhat inhibition of tumor growth. 
However, the mice treated with 50 and 100 mg/kg have the 
best effects in suppression of tumor growth (Figure 3). Thus, 
we selected the dose of 50 mg/kg as the optimum effective 
dose and used for subsequent in vivo experiments.
3.4. Inhibition of tumor growth by Cyt D
  The antitumor activities of Cyt D were observed in vivo in 
CT26 tumor model. CT26-bearing BABL/c mice were treated 
with Cyt D and DMSO, respectively, and tumor volumes 
(Figure 4A) and survival time (Figure 4B) were observed. 
Compared with the mice treated with DMSO, the mice treated 
with Cyt D were showed significant inhibition of tumor 
growth and prolong survival time (Figure 4). Both tumor 
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volume and survival time were found significant differences 
at day 16 after CT26 tumor cell injection (Figure 4, P < 0.01 
or less).
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Figure 3. Decision of the optimum effective dose of Cyt D. 
CT26 mice were randomly divided into five groups (n = 5) and injected 
with the indicating does of Cy D or DMSO every 3 days for 15 days. 
The results showed the tumor weight on day 18. Data are expressed as 
means 依 SEM, *P < 0.01.
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Figure 4. Inhibition of tumor growth by Cyt D. 
CT26 model mice were randomly divided into two groups (n=10) and 
injected i.v. with Cyt D and DMSO, respectively. Tumor volume (A) 
was significantly inhibited and prolonged survival rate (B) was found 
in the Cyt D mice when compared with the DMSO control mice. Data 
are expressed as means 依 SEM, * P < 0.05 or less.
3.5. Inhibition of angiogenesis by Cyt D
  Angiogenesis within tumor tissues was estimated through 
counting the number of microvessels on the sections stained 
with an antibody against to CD31. Compared with mice 
treated with DMSO, the average number of microvessels per 
high-power field (hpf) was significantly decreased in the 
mice treated with Cyt D (Figure 5A), 25.71 依 2.94 in the Cyt 
D-treated mice versus 69.23 依 4.62 in the DMSO-treated 
mice (Figure 5B, P < 0.001). In addition, the inhibition of 
angiogenesis in the mice treated with Cyt D was confirmed 
in alginate encapsulation assay. The alginate-implanted 
angiogenesis was quantified by measuring the uptake of 
FITC-dextran into the beads. The FITC-dextran uptake was 
also significantly decreased in the mice treated with Cyt 
D when compared with the mice treated with DMSO, 1.71 
依 0.23 (毺g/bead) in the Cyt D-treated mice versus 4.32 依 
0.48 in the DMSO-treated mice (Figure 5C, P < 0.001). These 
results indicated that the anticancer activities of Cyt D were 
related to the capabilities of inducing inhibition of tumor 
angiogenesis.
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Figure 5. Inhibition of angiogenesis by Cyt D.
Frozen sections of tumor tissues were tested by immunohistochemical 
analysis. The vasculatures in the tumor tissue were shown (A) and 
quantified (B). Alginate beads containing tumor cells were implanted 
into the mice, and the mice were then treated with Cyt D or DMSO. 
Thereafter, FITC–dextran in the beads was quantified (C). Data are 
expressed as means 依 SEM, * P < 0.001.
4. Discussion
  Cytochalasins are mainly isolated from tropical symbiotic 
fungi in tropical plants. When they were first isolated, 
scientists were considered them as possible cytotoxic agents 
and tried to use in cancer therapy. Several lines of evidence 
have demonstrated that cytochalasins can act on cell and 
tissue morphology and function in vitro among normal 
and cancer cells[17-22]. Cytochalasins can affect many cell 
fuctions, including adherence, cell motility, drug efflux, 
secretion, indicating that the cytochalasins might induce 
significant responses in experimental cancer chemotherapy 
model systems either as individual agents or, more likely, 
as agents amplifying responses induced by known antitumor 
drugs[14]. Up to now, many study results have indicated that 
cytochalasin D (Cyt D) is the most specific cytochalasins 
acting on the microfilaments. Thus, it is conceivable that 
Cyt D may potentially be a cytotoxic agent for cancer 
therapy. In this study, we used murine colorectal tumor 
cell line CT26 to investigate the possible Cyt D’s anticancer 
activities in vitro and in vivo. Results from cell proliferation 
assay by MTT method showed that Cyt D inhibited CT26 cell 
proliferation in a dose and time dependent pattern, and 
the climax inhibition ratio reached almost at 80 percent. 
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A TUNEL-based assay to detect the CT26 cell apoptosis in 
vitro indicated that Cyt D had strong capabilities of inducing 
CT26 cell apoptosis, Cyt D (7.5 毺g/mL) induced CT26 tumor 
cell apoptosis almost reaching the level induced by positive 
control nuclease. As we know, inhibition of tumor cell 
proliferation and induction of tumor cell apoptosis are two 
major mechanisms by which cytotoxic agents act on cancer 
cells. Chemotherapy, radiation therapy, and immunotherapy 
all rely heavily on inhibition of proliferation and apoptosis 
to kill cancer cells[23-25]. Thus, our in vitro results in the 
current study suggest that Cyt D is a excellent cytotoxic 
agent and has the potential prospects for using in cancer 
therapy.
  Although in vitro results in our current study suggest Cyt 
D is a potential cytotoxic agent to CT26 tumor cells, it still 
keep uncertain whether Cyt D can suppress tumor growth 
in vivo. To answer this question, we established CT26 tumor 
model in BALB/c mice and used Cyt D as a therapeutic agent 
to investigate the Cyt D’s anticancer activities. We found 
that Cyt D 50 mg/kg could significantly inhibit tumor growth, 
tumor weigh and tumor volume in the tumor model mice 
treated with Cyt D showed significantly decreased when in 
comparison with the mice treated with the control DMSO. 
The survival time in the mice treated with Cyt D was also 
significantly longer than those mice treated with control 
DMSO. In addition, our results also showed that Cyt D could 
suppress tumor angiogenesis in CT26 tumor model. Results 
from direct observation of tissue used immunohistochemistry 
method and alginate capsulated tumor cells to quantify the 
uptake of the FITC-dextran showed significant decreased 
blood vessels in the mice treated with Cyt D, when compared 
with the control mice treated with DMSO. Taken together, 
our results indicate that Cyt D may be a potential cytotoxic 
agent for treatment of colorectal tumor.
  As we know, the growth and persistence of solid tumors 
and their metastases depend majorly on angiogenesis[26, 27].
Therefore, anti-angiogenic therapy, which targets 
genetically stable endothelial cells, is also an optimal 
alternative for the treatment of tumors. Combination of these 
two strategies for tumor therapies has indicated a promising 
advantage in many previous preclinical studies[28-30]. The 
results in our current study showed that Cyt D could induce 
inhibition of CT26 tumor angiogenesis. Although our results 
in this study do not unveil the possible mechanism by which 
Cyt D acts on the tumor angiogenesis, many previous studies 
indicated that almost all cytotoxic agents clinically used for 
cancer therapy have the capabilities of inhibition of tumor 
angiogenesis even in small dose. Tumor angiogenesis is 
related to endothelial cells, which are active cells as cancer 
cells, cytotoxic agents thus can kill the endothelial cells 
in the same mechanisms. Our in vitro results indicated 
that Cyt D could inhibit CT26 cell proliferation and induce 
cell apoptosis; we thus consider that both inhibition of cell 
proliferation and promotion of cell apoptosis by Cyt D are 
involved in the processes of inhibiting tumor angiogenesis 
in vivo. However, the exact molecular mechanisms behind 
these phenomena induced by Cyt D remain unknown and 
need to be further investigated in the future.
  Cyt D is a fungal metabolite that is capable of permeating 
cell membranes, binding to actin and altering its 
polymerization. At present, Cyt D is reported to be the most 
specific for the actin cytoskeleton among cytochalasins[13]. 
As we know, the Cyt D’s targets, microfilaments, are 
ubiquitous in eukaryotic cells, if Cyt D is considered to 
be used as a cytotoxic agent, it will be possible to induce 
extensive side effects. In this study, although we found Cyt D 
is possible an effective cytotoxic agent for treatment of CT26 
tumor, we did not perform experiments to investigate its side 
effects. Thus, detailed and systematic studies are need to 
be carried out to investigate the possible side effects when 
consider using Cyt D as an anticancer agent in the further. 
  In summary, we used murine colorectal tumor cell line 
CT26 to investigate the possible anticancer activities of Cyt 
D in vitro and in vivo. Our study results suggested that the 
Cyt D could effectively induce inhibition of CT26 tumor cell 
proliferation and cell apoptosis in vitro, and caused tumor 
suppression of CT26 tumor growth and angiogenesis in vivo. 
Thus, Cyt D may be potentially used as a cytotoxic agent for 
cancer therapy.
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